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Background/aim: Aldosterone is a mineralocorticoid that secreted from adrenal glands and a known factor to increase magnesium
excretion by direct and indirect effects on renal tubular cells. Although the frequency of hypomagnesemia was found to be approximately
5% in adult studies, there is no study in the literature investigating the frequency of hypomagnesemia in children by using fludrocortisone,
which has a mineralocorticoid activity.
Materials and methods: A multi-center retrospective study was conducted, including children who were under fludrocortisone
treatment for primary adrenal insufficiency and applied to participant pediatric endocrinology outpatient clinics.
Results: Forty-three patients (58.1% male, 41.9% prepubertal) included in the study, whose median age was 9.18 (0.61-19) years, and the
most common diagnosis among the patients was a salt-wasting form of congenital adrenal hyperplasia (67.4%). Mean serum magnesium
level was 2.05 (±0.13) mg/dL, and hypomagnesemia was not observed in any of the patients treated with fludrocortisone. None of the
patients had increased urinary excretion of magnesium.
Conclusion: Unlike the studies performed in adults, we could not find any evidence of magnesium wasting effect of fludrocortisone
treatment with normal or even high doses in children and adolescents.
Key words: Mineralocorticoids, magnesium, magnesuria, pediatrics, primary adrenal insufficiency

1. Introduction
Magnesium is an inorganic ion, which is mostly stored
at intracellular space, especially in bones. There is not
any specific hormone that regulates serum levels of
magnesium, homeostasis of which is primarily sustained
by gastrointestinal absorption and renal excretion [1].
About 80% of plasma magnesium is filtered through the
glomerulus in kidneys and partially reabsorbed at the
proximal tubule first. Most of the filtered magnesium
is reabsorbed at the thick ascending limb of the loop
of Henle, and approximately 5%-10% is reabsorbed at
the distal convoluted tubule, depending on the voltage
gradient, which is created by potassium secretion into the
distal tubule. This process in distal tubule is an essential
physiological factor for magnesium balance [2,3].
Aldosterone is a mineralocorticoid that secreted
from adrenal glands and has a regulator effect on blood

pressure, water, and electrolyte homeostasis. It increases
sodium (Na+) reabsorption in both distal, connecting
tubules or collecting ducts of the nephrons [4]. Also,
aldosterone is known to increase magnesium excretion
by direct and indirect effects on renal tubular cells [5].
The transient receptor potential melastatin-7 (TRPM7) is
one of the main ion channels thought to be responsible
for this effect [6-8]. Although the data for explaining this
are very limited and contrasting, there were reported cases
of hyperaldosteronism, concomitant with magnesium
deficiency and increased renal magnesium excretion
[5,9,10].
Fludrocortisone has mineralocorticoid activity and
is used in the treatment of primary adrenal insufficiency
(PAI) in children. Among the side effects of fludrocortisone,
hypertension, and electrolyte disorders are frequently
seen [11,12]. The most common electrolyte disorder
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is hypokalemia and has been reported in about 50% of
patients. The frequency of hypomagnesemia was found to
be approximately 5% in adult studies [13]. However, there
is no study in the literature investigating the frequency of
hypomagnesemia in children using fludrocortisone.
In this study, we aimed to investigate the frequency of
hypomagnesemia in children who received the diagnosis
of PAI and treated with fludrocortisone.
2. Materials and methods
A multicenter retrospective study was conducted, including
patients aged 0-19 years who were under fludrocortisone
treatment for PAI and applied to pediatric endocrinology
outpatient clinics between August and December 2019. The
diagnostic categories were registered as follows: congenital
adrenal hyperplasia, autoimmune adrenalitis, X-linked
adrenal hypoplasia congenita, adrenalectomy, and others.
Patients who had a transient case of adrenal insufficiency,
adrenal dysfunction according to hypothalamic, and
pituitary disorders or patients who did not receive
fludrocortisone treatment were excluded.
Data including date of birth, age at diagnosis, sex,
clinical presentation, treatment modalities and durations,
age at the onset of treatment were collected from patients’
clinical records. The following data were obtained from
these patients on their clinical follow-up at pediatric
endocrinology outpatient clinics: weight (kg), height
(m), body mass index (kg/m2), blood pressure (mmHg),
pubertal stage according to Tanner [14], serum and
urine electrolytes, serum cortisol, adrenocorticotropic
hormone (ACTH), parathormone, alkaline phosphatase,
25-OH vitamin D and plasma renin activity. All tests were
performed early in the morning between 8-9 AM. The
reference values for spot urine calcium and magnesium
were 0.9-37.9 mg/dL and 2.09-23.21 mg/dL, respectively.
The normal range of spot urine magnesium/creatinine
ratio was 0.11-0.21. Plasma renin activity level was defined
as high when it was greater than the upper limit for ages
given as follows: 37 ng/mL/h under 1-year of age, 10 ng/
mL/h for 1 to 3-years, 7 ng/mL/h for 3 to 15-years, 9 ng/
mL/h above 15-years of age [15].
Standard deviation scores (SDS) for weight, height, and
body mass index were calculated with the online calculator
for pediatric endocrinologists (Child Metrics) [16] using
the reference created for the Turkish population by Neyzi
et al. [17]. Blood pressure measurements were interpreted
according to percentile values for the appropriate age,
height, and sex [18]. Bone age assessment was performed
according to Greulich-Pyle radiographic atlas, with the
left-hand wrist radiograph of each case [19].
Primary adrenal insufficiency diagnosis was made
according to the criterias as follows: (a) clinical symptoms
and signs suggestive of PAI, such as hyperpigmentation,
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distinctive electrolyte imbalance, salt craving; (b) ACTH
plasma levels measured at 8 AM were higher than the
reference range for two times, concomitant with a cortisol
level of < 140 nmol/L (5 µg/dL); (c) a variant in a gene whose
mutation known to cause PAI [20]. The fludrocortisone
treatment was given to all patients with PAI, as well as
patients with simple virilizing form of congenital adrenal
hyperplasia who had elevated plasma renin activity levels
or showed symptoms of mineralocorticoid deficiency. The
dose of fludrocortisone was considered as a high dose
in those who received more than 150 µg/m2/day under
2-years of age, and more than 100 µg/m2/day over 2-years
of age [21].
This study was approved by the ethical committee of
Aydın Adnan Menderes University Faculty of Medicine
(Ethics approval number: 2020/80-20) and performed
according to the principles of the Declaration of Helsinki.
Signed informed written consent form was not obtained
due to the retrospective nature of the study.
2.1. Statistical analyses
All statistical analyses were performed using the SPSS
application for Windows version 24.0 (IBM Co., Armonk,
NY, USA). Clinical data were presented as number
(%), mean±standard deviation for normal distribution
and median (minimum-maximum value) for data that
were not distributed normally. For statistical analysis,
comparisons were performed with the ındependent
samples test (student’s t-test) or the Mann–Whitney U test
as appropriate. The Pearson correlation test was applied for
correlations between the parameters. A P-value of <0.05
was considered statistically significant.
3. Results
Forty-three patients (58.1% male, 41.9% prepubertal)
included in the study, whose median age was 9.18 (0.61–
19) years, bone age was 10.75 (0.4 - 18.5) years and age of
diagnosis was 29 days (3 days–17 years). Anthropometric
measurements of the patients were given in Table 1.
The most common diagnosis among the patients was
congenital adrenal hyperplasia salt-wasting form (67.4%).
Other diagnoses were found as follows: simple virilizing
form of congenital adrenal hyperplasia (18.6%), X-linked
adrenal hypoplasia congenita (4.7%), autoimmune
adrenalitis (2.3%), adrenalectomy (2.3%) and other causes
of PAI (4.7%). There was a consanguinity between the
parents in 23.3% of the patients.
Patients had been treated with fludrocortisone for 6.48
(0.58–15.58) years, and the median dose was 0.1 (0.025–
0.2) mg/day corresponded to 80.5 (28.09–390.73) µg/m2/
day. Fourteen patients were found as receiving a high dose
of fludrocortisone. Mean hydrocortisone treatment dosage
was 13.08 (± 5.86) mg/m2/day. Median percentile values
of systolic and diastolic blood pressure were calculated as
81.5 (8–99) and 88.5 (22–99), respectively (Table 1).
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Table 1. Anthropometric measurements and treatment
characteristics of the patients.
Age (years)

9.18 (0.61–19)

Bone age (years)

10.75 (0.4–18.5)

Weight SDS

0.29 [(-1.9)–(3.1)]

Height SDS

-0.24 [(-2.7)–(1.9)]

Body mass index SDS

0.36 [(-1.4)–(3.8)]

Systolic blood pressure percentile

81.5 (8–99)

Diastolic blood pressure percentile

88.5 (22–99)

Fludrocortisone treatment duration (years)

6.48 (0.58–15.58)

Fludrocortisone dosage (µg/m2/day)

80.5 (28.09–390.73)

Hydrocortisone dosage (mg/m /day)

13.08 (± 5.86)

2

The data were presented as mean±standard deviation for normal
distribution and median (minimum–maximum value) for that
were not distributed normally. SDS: standard deviation score.

The serum magnesium level was found to be 2.05 (± 0.13)
mg/dL, and hypomagnesemia was not observed in any of the
patients treated with fludrocortisone. Mean serum sodium,
potassium, and chloride values were in normal ranges. Tests
about the bone metabolism were found as follows: serum
calcium 9.80 (± 0.47) mg/dL, phosphorus 4.60 (± 0.57)
mg/dL, alkaline phosphatase 198.2 (± 84.5) IU/L, 25-OH
vitamin D 20.5 (± 6.57) ng/Ml, and parathormone 43.9 (±
18.1) pg/mL. Median levels for ACTH, cortisol, and plasma
renin activity were 51.6 (5–1250) pg/mL, 7.90 (0.40–60.1)
µg/dL, and 3.01 (0.1–13.5) ng/mL/hour, respectively (Table
2). Plasma renin activity was higher than the upper limit for
age in seven patients. None of the patients complained of
tetany or involuntary contractions.
The median values 
of spot urine calcium and
magnesium excretion were found as 4.43 (0.03–14.34)
and 6.89 (1.09–19.53) mg/dL, respectively. Spot urine
calcium/creatinine ratio was calculated as 0.05 (0.01–0.54)
and magnesium/creatinine as 0.09 (0.02–0.39) (Table 2).
None of the patients had increased urinary excretion of
magnesium. There was no significant difference found in
urinary or serum magnesium levels between the groups
according to plasma renin activity levels (normal or high)
(P > 0.05). Although spot urine magnesium level was higher
in the group that received high dose fludrocortisone, there
was no significant difference between the high dose- or
normal dose-fludrocortisone given groups (P > 0.05). Also,
serum magnesium and plasma renin activity levels were
similar in these two groups (P > 0.05) (Table 3). There
was no significant correlation between serum and urinary
magnesium levels and hydrocortisone or fludrocortisone
dosage, fludrocortisone usage time, or plasma renin activity
(P > 0.05).

4. Discussion
Primary adrenal insufficiency is a rare clinical condition
characterized by the insufficient production of the steroid
hormones from the adrenal cortex, such as cortisol,
aldosterone, and adrenal sex steroids, affecting both sexes
equally in childhood [22–24]. The main treatment of
PAI is replacing glucocorticoids and mineralocorticoids,
principally by hydrocortisone and fludrocortisone [21,22].
The recommended dosage for hydrocortisone ranges
between 7.5–15 mg/m2/day, according to the underlying
cause [25–27]. Fludrocortisone is the only available
mineralocorticoid and used as a single dose of 0.05–0.2
mg/day orally, or with a dose of 100–150 µg/m2/day
according to the age of the patient. For children receiving
fludrocortisone treatment, blood pressure, electrolytes,
and plasma renin activity should be monitored.
Normotension, normokalemia, and an upper-normal
ranged plasma renin activity indicates adequate dosage for
fludrocortisone treatment [21,25,28]. Our treatment doses
with hydrocortisone and fludrocortisone were 13.08 mg/
m2/day and 80.5 µg/m2/day, respectively. Although there
were several patients with hypertension, median values of
blood pressure percentiles and plasma renin activity were
in normal ranges. Also, serum electrolyte levels of our
patients were within the normal ranges.
Magnesium is an intracellular cation, and its
serum concentration is kept between 1.8–2.5 mg/dL
corresponding to 1% of the total body magnesium [29]. It is
held at this level, especially by the balance of reabsorption
and excretion mechanisms in the kidneys, which take
place mainly at the loop of Henle and proximal or distal
tubules. The reabsorption in the distal tubule is essential
for the physiological process in fine-tuning of magnesium
level [2,8]. Transient receptor potential melastatin-6
(TRPM6) is an essential magnesium transporting channel
[30]. An autosomal dominant inherited variant of KCNA1,
which encodes the voltage-gated potassium channel
(Kv1.1) colocalized with TRPM6, reported as a rare cause
of isolated hypomagnesemia [31]. In addition, TRPM7 is
an omnipresently expressed, aldosterone-responsive ion
channel, that is magnesium permeable [6–8]. Aldosterone
was reported to increase intracellular magnesium levels and
TRPM7 signalling, via nongenomic and genomic signalling
cascades [32]. In the genomic pathway, aldosterone
augments the genomic expression of proteins involved in
electrolyte balance, by binding mineralocorticoid receptors
[33,34]. Nongenomic pathways include mineralocorticoid
receptor, EGF receptor, and G-protein coupled receptordependent mechanisms as well as mineralocorticoid
receptor-independent actions [35–39]. Valinsky et al. [4]
showed that aldosterone promotes the plasma membrane
expression of TRPM7, and therefore TRPM7 flow. These
processes occurred via genomic signalling cascades related
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Table 2. Laboratory findings of the patients.
Parameters

Results

Reference ranges

Serum sodium (mEq/L)

139.4 (± 2.53)

136–145

Serum potassium (mEq/L)

4.38 (± 0.36)

3.5–5.1

Serum chloride (mEq/L)

103.2 (± 2.55)

98–107

Serum calcium (mg/dL)

9.80 (± 0.47)

8.8–10.6

Serum magnesium (mg/dL)

2.05 (± 0.13)

1.8–2.6

Serum phosphorus (mg/dL)

4.60 (± 0.57)

3.7–5.4

Serum alkaline phosphatase (IU/L)

198.2 (± 84.5)

74–390

Serum 25-OH vitamin D (ng/mL)

20.5 (± 6.57)

>20

Serum parathormone (pg/mL)

43.9 (± 18.1)

14–72

Serum ACTH (pg/mL)

51.6 (5–1250)

0–46

Serum cortisol (µg/dL)

7.90 (0.40–60.1)

N/A

Plasma renin activity (ng/mL/h)

3.01 (0.1–13.5)

<37 under 1-year of age, <10 for 1 to 3-years, <7 for 3 to 15-years,
<9 above 15-years of age

Spot urine calcium (mg/dL)

4.43 (0.03–14.34)

0.9–37.9

Spot urine calcium/creatinine

0.05 (0.01–0.54)

0–0.21

Spot urine magnesium (mg/dL)

6.89 (1.09–19.53)

2.09–23.21

Spot urine magnesium/creatinine

0.09 (0.02–0.39)

0.11–0.21

The data were presented as mean ± standard deviation for normal distribution and median (minimum–maximum value) for that were
not distributed normally. ACTH: adrenocorticotropic hormone; N/A: not available.

Table 3. Comparison of the serum and urine magnesium levels of the patients grouped according to plasma renin activity and
fludrocortisone dosage, and plasma renin activity levels of the patients given normal or high dose of fludrocortisone.
Patients with normal plasma renin activity Patients with high plasma renin activity
P
(n = 34)
(n = 7)
Serum magnesium (mg/dL)

2.05 ± 0.15

2.03 ± 0.06

0.45a

Spot urine magnesium (mg/dL)

6.98 (1.09–19.53)

6.89 (2.65–12.31)

0.79b

Patients given normal dose of
fludrocortisone (n = 29)

Patients given high dose of
fludrocortisone (n = 14)

Serum magnesium (mg/dL)

2.03 ± 0.12

2.11 ± 0.14

0.05a

Spot urine magnesium (mg/dL)

6.58 (1.68–17.0)

7.71 (1.09–19.53)

0.27b

Plasma renin activity (ng/mL/h)

2.75 (0.1–9.22) (n = 27)

3.27 (0.17–13.52)

1.00b

The data were presented as mean±standard deviation for normal distribution and median (minimum–maximum value) for that were
not distributed normally. aStudent’s t-test, bMann-Whitney U test, P < 0.05.

to mineralocorticoid receptors. They also reported that
eplerenone, a mineralocorticoid receptor blocker, inhibited
the TRPM7 current [4]. On the other hand, Sontia et al.
[40] showed that aldosterone reduced expression of renal
TRPM7 without effecting TRPM6. These experimental
findings suggest that mineralocorticoid receptors play an
essential role in magnesium metabolism via TRPMs.
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Ichihara et al. [41] showed magnesium as a regulator
for aldosterone production. Aldosterone was reported to
increase the clearance and excretion of renal magnesium
and calcium with normal serum levels [5], although
there have been contrary findings that acute effects of
mineralocorticoids failed to alter magnesium or calcium
excretion [42]. Therefore, it was suggested that increased
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excretion of magnesium or calcium could be a long term
action of mineralocorticoids. Horton et al. [5] reported
that urine magnesium levels were decreased after
spironolactone administration in patients with primary
aldosteronism. Resnick and Laragh [43] reported serum
magnesium levels in the normal range but higher than
the control group in patients with primary aldosteronism.
Also, they suggested that parathyroid hypersecretion is a
common finding of primary aldosteronism. Delva et al.
[9] showed no difference between levels of total plasma
or urinary magnesium, and total plasma calcium within
primary aldosteronism and control groups. However, they
found intracellular ionized magnesium concentration
significantly lower in patients with primary aldosteronism
than the control group. They suggested that aldosterone
could cause these effects on the magnesium homeostasis
by alteration of the sodium-magnesium antiporter
activity [9]. Furthermore, Matsouka [10] reported that
secondary hyperaldosteronism caused by diuretics
increased potassium and magnesium excretion in urine,
and also aldosterone antagonists like eplerenone or
spironolactone reversed this effect. Despite being treated
with fludrocortisone, we found that our patients with PAI
had serum and urine magnesium levels in the normal
range. Also, their serum or urine calcium and serum
parathormone levels were in the normal range, too.
In an experimental study, after the onset of
mineralocorticoid treatment in rats, highly elevated
levels of magnesium were detected in urine [44]. Among
the side effects of fludrocortisone, the frequency of
hypomagnesemia was known to be approximately 5%
in adult studies [13]. While this was a classical textbook
data, we could not find the related article, so the clinical
and biochemical characteristics of these adult patients
with hypomagnesemia are not known. O’Connor et al. [45]
presented a 27-year-old female case with hypomagnesemia
who was diagnosed as an autoimmune polyglandular
syndrome and had been given 0.3 mg/day fludrocortisone
therapy. In addition, elevated levels of serum magnesium
and potassium levels were returned to normal after the
onset of mineralocorticoid replacement in two infants with
the salt-wasting form of congenital adrenal hyperplasia
[46]. Unlike the literature data gained from molecular and
clinical studies with adults, we could not find any evidence
of hypomagnesemia or renal magnesium wasting in
children treated with fludrocortisone. Although this result
may be related to the limited number of cases in our study,

it suggested that the dose of fludrocortisone we used in our
patients was not high enough to increase the excretion of
magnesium in the urine as shown in hyperaldosteronism,
even in patients that received 3–4 folds higher doses.
Therefore, it may be associated with varying responses of
mineralocorticoid receptors according to age.
To our knowledge, this is the first study to investigate the
magnesium wasting effect of the fludrocortisone treatment
in children with PAI. However, there were some limitations
in our study. First of all, it was a retrospective study and the
sample size was relatively small. Secondly, we were not able
to include an age-matched control group to compare the
results with healthy children due to ethical issues. Also, we
could not be able to collect a 24–h urine specimen to assess
magnesium excretion due to the retrospective nature of
the study, which is a more accurate method regarding the
circadian rhythm of renal magnesium excretion. Therefore,
we used spot urine magnesium levels, which is more
practical and compatible with the daily clinical practice, but
might be less accurate for measuring fractional excretion
of magnesium. Hence, further prospective case-control
studies with larger sample sizes and also molecular studies
will be helpful to reveal this controversial subject and the
underlying pathophysiological mechanisms in childhood.
In this study, unlike the studies performed in adults, we
could not find any evidence of magnesium wasting effect
of fludrocortisone treatment with normal or even high
doses in children and adolescents. Therefore, contrary to
the recommendations for adults, we do not recommend
routine monitoring of serum magnesium levels in these
children. Although aldosterone is known to increase the
excretion of magnesium by effecting renal tubular cells
directly or indirectly, fludrocortisone did not seem to be
causing these effects in appropriate dosages for replacement
in children and adolescents.
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